Limited Offer
Early Vascular Aging (EVA)
New Directions in Cardiovascular Protection
- 2nd Edition - February 29, 2024
- Editors: Pedro Guimarães Cunha, Pierre Boutouyrie, Michael Hecht Olsen, Peter M Nilsson, Stephane Laurent
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 5 5 1 2 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 5 5 1 3 - 0
Early Vascular Aging (EVA): New Directions in Cardiovascular Protection, Second Edition continues to be the most comprehensive and authoritative resource on premature altera… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote- Contains all the relevant information available on the main paradigm shifts in vascular aging research, from different fields of knowledge (from basic biology to epidemiology)
- Reviews the most prominent evidence produced on early vascular aging (EVA), highlighting recent research advances, clinical applications, and research opportunities
- Formulates, in each chapter, a set of research questions that need to be addressed, challenging the vast research community to take on new directions and collaborations
- Cover image
- Title page
- Table of Contents
- Front Matter
- Copyright
- Contributors
- In Memoriam
- Preface
- References
- Section 1: Introduction
- Introduction
- Chapter 1 Historical Aspects and Biology of Aging
- Abstract
- Acknowledgment
- Evolutionary Traits, Genes, and the Environment Influencing Aging
- Changes During the 20th Century in Life Expectancy
- Early Life Programming Effects
- Vascular Aging in Perspective
- Longevity Blue Zones and Vascular Aging
- New Models and Interventions to Influence Aging
- References
- Chapter 2 The 9 Paradigm Shifts in Cardiovascular Aging Research
- Abstract
- Introduction
- Section 1: Paradigm Shifts in Vascular Aging Concepts
- Section 2: Paradigm Shifts in Early Vascular Aging
- Section 3: Paradigm Shift in Cardiovascular Intervention
- Conclusions
- References
- Chapter 3 Vascular Aging and Cardiovascular Disease
- Abstract
- Changes With Age in the Arterial Tree
- Monitoring Vascular Aging and Detecting Accelerated Signs of Vascular Deterioration
- Central Hemodynamic Variables and Association to Cardiovascular Risk
- Conclusions and Future Perspectives
- References
- Section 2: Lifecourse Approach and Population Based Studies
- Introduction
- Chapter 4 Aging Population: Challenges and Opportunities in a Life Course Perspective
- Abstract
- Acknowledgments
- Aging Populations: Between Decreasing Mortality and Improved Health
- Living Longer, But With More Chronic Diseases
- From Healthcare of Older Subjects to a Life Course Approach
- Strategies for Healthy Aging
- References
- Chapter 5 Population-Based Studies: Milestones on the Epidemiological Timeline
- Abstract
- Introduction
- Proven Prognostic Power in High-Risk Subpopulations
- Proven Prognostic Power in the General Population
- Beyond Curve Divergence
- Data Harmonization
- The Rise of Novel PWV Measurements
- PWV Trajectories
- Quo Vadis: More Depth and Breadth of Phenotyping, More Comprehensive Populations, Longer Event Horizons
- More Depth and Breadth of Phenotyping: Wave Reflection
- More Depth and Breadth of Phenotyping: Time-Varying Phenomena
- More Comprehensive Populations: Studying the Early Impact of Cardiovascular Risk Factors
- More Comprehensive Populations: Early Vascular Aging and Stroke-Prone Populations
- Longer Event Horizons
- Mendelian Randomization: The Unbiased and Longest Event Horizon
- Conclusion
- References
- Lifetime Perspective of Vascular Aging
- Introduction
- Chapter 6 a. Lessons From the Amsterdam Growth and Health Longitudinal Study
- Abstract
- Acknowledgments
- Part 1: AGAHLS—The Cohort Profile
- Part 2: Early Determinants of Arterial Stiffness—A Life Course Approach
- Part 3: Findings From Other Life Course Studies Than the AGAHLS—A Comparison of Findings
- Part 4: Interpretation and Conclusions
- References
- Chapter 7 b. Cardiovascular Aging: Perspectives From Longitudinal Studies of Aging
- Abstract
- Sources of Funding
- Introduction
- Conceptual Approach to CV Aging Studies
- Detecting Occult CV Disease in BLSA Participants
- Subclinical Age-Associated Changes in Arterial Structure and Function
- The Link That Bridges Age to Early Atherosclerosis (The Validate Study)
- Arterial-Ventricular Uncoupling With Aging
- Summary
- References
- Chapter 8 c. Lessons From the Cardiovascular Risk in Young Finns Study
- Abstract
- Introduction
- Incorporating Markers of EVA in the Young Finns Study
- Life-Course Risk Factors and Markers of EVA
- Life-Course Risk Factors and Prediabetes and Type 2 Diabetes
- Cognitive Function in Young and Middle-Aged Adults
- From Young Finns to Younger Finns: A Multigenerational Approach to Vascular Health
- Conclusion
- References
- Chapter 9 Early Vascular Aging in the Young
- Abstract
- Introduction
- Development of the Vasculature During Fetal Life and Early Childhood
- Influence of Birth Weight on Blood Pressure
- Impact of Birth Weight on Vascular Structure and Function
- Influence of IUGR/SGA Phenotype on Arterial Structure and Function
- Influence of Prematurity on Arterial Structure and Function
- Influence of IUGR versus Prematurity
- Influence of Extreme Prematurity on Vascular Structure and Function
- Effects of Increased “Catch-Up” Growth Patterns
- Development of Atherosclerosis and Vascular Dysfunction Early in Life
- Challenges in Assessment of the Vasculature in Children
- Effect of Cardiovascular Risk Factors on Vascular Health in Children and Adolescents
- Summary, Future Directions, and Gaps in Knowledge
- References
- Chapter 10 Ethnicity and Arterial Function
- Abstract
- Early Childhood Studies
- Childhood Indices Predicting Adult PWV
- New Adult Data Since 2020
- Inflammation Indices
- Conclusion
- References
- Section 3: Molecular, Cellular and Mechanistic Contributions to Vascular Aging
- Introduction
- Chapter 11 Cellular and Molecular Determinants of Arterial Aging
- Abstract
- Growth Factors and Transcription Factors
- Cytoskeletal and Contractile Proteins in the Aging Arterial Wall
- Cellular Matrix Structure in the Aging Arterial Wall
- Proinflammatory Molecular, Cellular, and Vascular Events in the Aging Arterial Wall
- Antiinflammatory Pathways
- Conclusion
- References
- Chapter 12 Platelet/Leukocyte–Vessel Wall Interactions and Early Aging
- Abstract
- Platelet–Vessel Wall Interactions in Hemostasis
- Regulation of the Adhesiveness of Platelets at the Vessel Wall
- Platelet–Leukocyte Interplay
- Age-Related Changes in Platelet–Vessel Wall Interactions
- Pharmacological Concepts to Alleviate Platelet–Vessel Wall Interactions in Age-Related Cardiovascular Diseases
- Conclusion
- References
- Chapter 13 Age-Induced Endothelial Dysfunction and Intima–Media Thickening
- Abstract
- Introduction
- Part 1: Age and Endothelial Dysfunction
- Part 2: Age and Intima–Media Thickening
- Summary
- References
- Chapter 14 Diabetes, Prediabetes, Metabolic Syndrome, and Large Artery Vascular Ageing
- Abstract
- Bullet Points
- Part 0: Introduction—A Background on Diabetes and the Metabolic Syndrome and an Overview of the Chapter
- Part 1: Hyperglycemia and Insulin Resistance: Pathophysiological Mechanisms Underlying Arterial Wall Damage and Cardiovascular Disease
- Part 2: Hyperglycemia and Insulin Resistance: Their Roles in Endothelial Dysfunction and Carotid Artery Remodeling
- Part 3: (Pre)diabetes and Large Artery Stiffness: A Vicious Circle
- Part 4: The Metabolic Syndrome and Large Artery Stiffness
- Conclusions
- References
- Chapter 15 The Cross-Talk Between the Macro- and the Microcirculation
- Abstract
- Acknowledgment
- Introduction
- Small Artery in Normal and Accelerated Aging
- Functional Consequences and Target Organ Damage
- Large-Artery Remodeling
- Large-/Small-Artery Cross-Talk and Central Pulsatility
- Large-/Small-Artery Cross-Talk and Target Organ Damage
- Cardiovascular and Renal Outcome
- Conclusion
- References
- Chapter 16 Changes in Peripheral Blood Pressure with Normal and Accelerated Aging
- Abstract
- Introduction
- What Induces Accelerated Vascular Aging?
- Changes in Peripheral BP During Normal Aging
- Changes in Peripheral BP During Accelerated Aging
- Predictors of Diastolic Hypertension
- Predictors of ISH in Adolescents and Young Adults
- Predictors of ISH in Middle-Aged and the Elderly Subjects
- The Value of Paired BP Components in Predicting CVD Risk
- The Role of J-Curves in Predicting CVD Risk
- Perspectives
- References
- Chapter 17 Changes in Arterial Stiffness with Normal and Accelerated Aging
- Abstract
- Introduction
- A Word of Caution on Study Design
- Pathophysiology of Accelerated Vascular Aging
- Exploring Normal and Accelerated Aging of the Arteries in Cross-Sectional Studies
- Exploring Normal and Accelerated Aging of the Arteries in Longitudinal Studies
- Conclusions and Perspectives
- References
- Chapter 18 Changes in Central Hemodynamics, Wave Reflection, and Heart–Vessel Coupling with Normal and Accelerated Aging
- Abstract
- Introduction
- The Heart and its Interaction with the Arterial Tree
- Aging and Wave Reflections
- Central Arterial Pressure
- References
- Chapter 19 Arterial Stiffness and Blood Pressure Variability
- Abstract
- Introduction
- Blood Pressure Variability: A Complex Phenomenon
- Relationship of Arterial Stiffness With Blood Pressure Variability
- Arterial Stiffness as a Determinant of BPV
- Increased BPV as a Determinant of Arterial Stiffness: The Chicken or the Egg Question or a Bidirectional Relationship?
- Conclusions
- References
- Chapter 20 Chronic Inflammation in Atherosclerosis and Arteriosclerosis
- Abstract
- Acknowledgment
- Age and Development of Atherosclerosis
- Inflammation and Plaque Formation According to the Response-to-Retention Theory
- Evidence for the Role of Inflammation in Atherosclerosis
- The Role of Cytokines and Chemokines
- Regulation and Resolution of Inflammation
- Factors Increasing Vascular Aging
- Inflammation as a Therapeutic Target
- Concluding Remarks
- References
- Chapter 21 Nonhemodynamic Components of EVA: Polycystic Ovary Syndrome (PCOS)
- Abstract
- Acknowledgments
- Introduction
- Definition of PCOS
- PCOS and Risk Factors of Cardiovascular Disease
- PCOS Phenotypes and Cardiometabolic Risk
- Subclinical Arterial Disease in Women With PCOS
- Cardiovascular Disease Outcomes in Women With PCOS
- Conclusions
- References
- Chapter 22 Microbiota, Diet, Oral Health, and Vascular Aging
- Abstract
- Introduction
- Gut Microbiota and Early Vascular Aging
- Dietary and Nutritional Factors Affecting Vascular Aging
- Oral Health and Vascular Aging
- Conclusion
- References
- Section 4: Biomarkers, Risk Prediction and Phenotypes of Vascular Aging
- Introduction
- Chapter 23 Traditional Versus New Models of Risk Prediction
- Abstract
- Introduction
- Biomarkers and Risk Factors
- Risk Estimation Using Markers of Subclinical Organ Damage
- Future Research
- Summary
- References
- Chapter 24 Estimated Arterial Stiffness
- Abstract
- Introduction
- The Prognostic Value of ePWV
- Perspectives
- References
- Chapter 25 Vascular Aging Biomarkers: Methodological Measurement Consensus and Reference Values
- Abstract
- Introduction
- Methods Measuring the Transit Time of Pulse Wave
- Cuff Measurements
- Methods Estimating PWV
- Atypical Methods
- Arterial Stiffness Used for Blood Pressure Measurement
- Methods Measuring Arterial Distension
- Conclusion
- References
- Chapter 26 Imaging Biomarkers: Carotid Intima-Media Thickness and Aortic Stiffness as Predictors of Cardiovascular Disease
- Abstract
- Introduction
- Carotid Intima-Media Thickness and CV Prognosis
- How to Assess cIMT by Duplex Ultrasound
- Associations Between cIMT and Traditional CV Risk Factors
- Carotid IMT as a Predictor of CV Events
- Studies in Healthy Population (Table 26.1)
- Studies in Higher CV Risk Groups
- Carotid IMT Progression and CV Events
- What Is the Clinical Value of cIMT Measurement?
- Aortic Stiffness and CV Prognosis
- Carotid-Femoral Pulse Wave Velocity
- Brachial-Ankle Pulse Wave Velocity
- Estimated Pulse Wave Velocity
- Conclusion
- References
- Chapter 27 Imaging Biomarkers: Flow-Mediated Dilation as Predictor in Cardiovascular Disease
- Abstract
- Introduction
- Endothelial Function in Health and Disease
- Methods for Assessment of Endothelial Function: An Overview
- Flow-Mediated Dilation: Methodological Aspects
- Flow-Mediated Dilation in Cardiovascular Disease Prediction and Other Clinical Applications
- Flow-Mediated Dilation: Emerging Techniques
- Perspectives
- Conclusions
- References
- Chapter 28 Genetic Markers in Predicting Three Common Vascular Diseases
- Abstract
- Acknowledgment
- Celebrating the Anniversary of the Discovery of the Structure of DNA and Improvements to Human Genome Sequencing
- Genomics as a Research Paradigm
- The Genotype Tissue Expression Project
- Linkage Disequilibrium in GWAS
- The Epidemic of Cardiovascular Disease
- Genetic Architecture of Coronary Artery Disease, Stroke, and Primary Hypertension
- Coronary Artery Disease
- Stroke
- Blood Pressure Regulation and Primary Hypertension GWAS
- Beyond Genome-Wide Association Studies
- References
- Chapter 29 Phenotypes of Vascular Aging
- Abstract
- Introduction
- Sex and Ethnicity
- Chronobiologic Asynchrony
- Arterial Stiffness (cfPWV > 10 m/s), HMOD Phenotypes, and Risk Reclassification
- New Hemodynamic Phenotypes
- Vascular Aging, Heart Failure Phenotypes, and Resistant Hypertension
- Conclusion: Vascular Aging Phenotypes
- References
- Section 5: Vascular Aging, Organ Damage and Late Stage Disease
- Introduction
- Chapter 30 Early and Late Stages of Chronic Kidney Disease in Relation to Arterial Changes
- Abstract
- Introduction
- Renal Microcirculation
- CKD as a Phenotype of Accelerated Vascular Aging: Pathophysiological Mechanisms
- Arterial Stiffness and CKD
- Arterial Stiffness After Kidney Transplantation
- Nephroprotective Medications and Vascular Changes
- Conclusions
- References
- Chapter 31 Arterial Aging, Blood Pressure, and Brain Damage
- Abstract
- Cognitive Decline and Dementia: The Emerging Role of Arterial Aging
- Structural Brain Changes and Aging
- Pathophysiological Considerations
- Arterial Stiffness, Pulsatility, and Brain Damage
- Pressure Dependency of Arterial Stiffness
- Therapeutic Opportunities and Research Perspectives
- Conclusions
- References
- Chapter 32 Clinical Implications of Ventricular-Arterial Coupling and the Role of Therapeutic Interventions
- Abstract
- Ventricular-Arterial Coupling in Hypertension and Diabetes
- Ventricular-Arterial Coupling in Systemic Inflammatory Disease
- Ventricular-Arterial Coupling in Valvular Heart Disease
- Ventricular-Arterial Coupling in Coronary Artery Disease
- Ventricular-Arterial Coupling in Heart Failure
- Right Ventricular-Arterial Coupling
- Ventricular-Arterial Coupling in Critically Ill Patients
- Ventricular-Arterial Coupling in Aortopathies
- References
- Chapter 33 Systemic Ventricular–Arterial Coupling and Heart Disease
- Abstract
- The LV Cycle in the Pressure–Volume Plane
- The Concept of Effective Arterial Elastance and Assessment of Ventricular–Arterial Coupling in the PV Plane
- Strengths and Limitations of the PV Plane
- Assessment of VAC via Analyses of Pressure–Flow Relations
- Wave Intensity Analysis
- Assessment of Time-Resolved Myocardial Wall Stress
- Physiologic Phenomena Affecting Time-Resolved MWS in Systole
- Other Approaches
- Clinical, Epidemiologic, and Mechanistic Considerations
- Disclosures
- References
- Section 6: Translating Research into Clinical Practice, with Precision Cardiovascular Medicine: Implications of Vascular Aging
- Chapter 34 Vascular Aging and Clinical Trials
- Abstract
- Introduction
- Rare Cardiovascular Diseases
- Using Wearable Devices
- Treatment Aspects
- Introduction
- Chapter 35 a. Part I: Treatment of Abnormalities in Lipid Metabolism and EVA
- Abstract
- What is Early Vascular Aging (EVA) and How Can it be Measured?
- Hyperlipidemia and EVA
- Treatment of Lipids and EVA
- Conclusions and Perspectives
- References
- Chapter 36 b. Part II: Early Vascular Aging and Obesity Treatment
- Abstract
- Introduction
- Why Weight Loss Data is Not Enough
- The Limits of Cardiovascular Outcomes Studies in Obesity
- Weight Loss and EVA Progression—Epidemiological Data
- Weight Loss and EVA Biomarkers in Clinical Studies
- Weight Loss Through Hypocaloric Diets
- Composition of Hypocaloric Diets
- Physical Exercise
- Weight Loss Medications
- Bariatric Surgery
- Conclusions and Open Questions
- References
- Chapter 37 c. Part III: Treatment with Antidiabetes Drugs—Effects on Blood Pressure and Central Hemodynamics
- Abstract
- SGLT-2 Inhibitors
- GLP-1 Receptor Agonists/Analogues
- Combination Therapy
- Conclusions
- References
- Chapter 38 d. Part IV: Arterial Stiffness as Treatment Target: The SPARTE Study
- Abstract
- Concept and Objectives
- Design and Methods
- Results
- Consideration for Clinical Practice
- References
- Chapter 39 Lifestyle Intervention: What Works?
- Abstract
- Smoking
- Diet and Nutrition
- Coffee
- Tea
- Cocoa
- Mediterranean Diet
- Ω-3 Fatty Acids
- Vitamins
- Salt
- Alcohol
- Exercise
- Obesity and Weight Loss
- Stress and Mental Health
- Air and Noise Pollution
- References
- Chapter 40 Targeting Blood Pressure Lowering and the Sympathetic Nervous System
- Abstract
- Tests for Studying the Human Sympathetic Nervous System
- Role of the Sympathetic Nervous System in Human Hypertension
- The Link Between the Sympathetic Nervous System and Arterial Stiffening
- Pharmacological Modulation of Arterial Stiffness
- Effect of Procedural Interventions on Arterial Stiffness and Sympathetic Outflow
- Future Directions
- References
- Chapter 41 Targeting Central Blood Pressure Through the Macro- and Microcirculation Cross-Talk
- Abstract
- Introduction
- Effects of Drugs on Small Artery Structure and Function in Hypertension
- Effects of Drugs on Large Artery Structure and Function in Hypertension
- Targeting Central Blood Pressure Through the Macro- and Microcirculation Cross-Talk
- Directions for Future Research
- Conclusion
- References
- Cardiovascular Aging in Clinical Guidelines
- Introduction
- Chapter 42 a. Cardiovascular Prevention Strategies in a Life Course Perspective
- Abstract
- Acknowledgment
- Prevention Starts Early
- Summary
- References
- Chapter 43 b. Cardiovascular Prevention Strategies in Patients With Comorbidities (Metabolic, Chronic Inflammation, Immunomodulation, Cancer, and Treatment-Induced Arterial Changes)
- Abstract
- Introduction
- European Guidelines
- American Guidelines
- Asian Guidelines
- Other Guidelines
- European League Against Rheumatism (EULAR)
- ESC—Cardio-oncology
- Conclusions
- References
- Chapter 44 c. Cardiovascular Risk Prediction
- Abstract
- Introduction
- Pulse Wave Velocity as a Screening Tool—Age Perspectives
- Pulse Wave Velocity as a Tool for Management of Hypertension
- Pulse Wave Velocity as a Tool to Improve Medication Adherence and Induce Beneficial Behavioral or Lifestyle Changes
- Conclusion
- References
- Chapter 45 d. Target Organ Damage
- Abstract
- Introduction
- Heart
- Other Imaging Techniques
- Coronary Calcium Score
- Carotid Intima–Media Thickness (IMT) and Plaque
- Aortic Stiffness (Pulse Wave Velocity)
- Ankle Brachial Index (ABI)
- Small Arteries
- Conclusions
- References
- Chapter 46 e. Therapeutic Implications of Early Vascular Aging
- Abstract
- References
- Introduction
- References
- Chapter 47 New Drugs Under Development for Cardiovascular Prevention
- Abstract
- Introduction
- New Molecules Targeting Isolated Systolic Hypertension
- New Drugs for Systolic-Diastolic Hypertension
- Current Pharmacological Classes, New Versus Old Molecules
- Old Drugs: New Combinations
- Other Possible Alternatives to Classical Drugs
- Conclusion
- References
- Chapter 48 Specific Pathways to Prevent Early Vascular Aging
- Abstract
- Introduction
- Vascular Aging
- Preventable Factors Leading to EVA
- Genetics–Epigenetics
- Spaceflight: A Model of Accelerated Vascular Aging
- Progeria: A Model of Extreme Early Vascular Aging
- Skin Aging
- Bone Aging
- Conclusion
- References
- Chapter 49 Immunization, Vaccines, and Immunomodulation
- Abstract
- Introduction
- Role of Immunity
- Immunization and Targeted Antigens
- Gene Therapy for Treating Hypertension
- Safety of anti-RAAS Vaccines and Gene Therapy
- Conclusion
- References
- Section 7: Global Mapping of Vascular Aging Research
- Introduction
- Cardiovascular Aging in Clinical Guidelines
- Introduction
- Chapter 50 a. European Research Centres
- Abstract
- The ARTERY Society. The Association for Research Into Arterial Structure and Physiology
- Clinical Pharmacology Unit—Hopital Européen Georges Pompidou-APHP (Paris, France)
- Lund University, Department of Clinical Sciences, Malmö, Sweden
- Arterial Aging From Bedside to Bench ...and Back
- The Maastricht study, The Netherlands: A population-based cohort study with oversampling of participants with type 2 diabetes
- Erasmus MC University Medical Center, Rotterdam, The Netherlands
- Acute and Chronic Cardiovascular Deficiency, Nancy, France
- Cardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria
- Department of Sport, Exercise and Health at University of Basel, Division of Sport and Exercise Medicine, Basel
- Biophysical Models for Medical Applications (BioMMedA), Ghent, Belgium
- Medical University of Gdansk, Poland
- Department of Geriatrics and Stroke Medicine, Brighton, UK
- Centre for the Research and Treatment of Arterial Hypertension and Cardiovascular Risk, Hospital Senhora da Oliveira/Minho University, Guimarães, Portugal
- Preventive Cardiology and Echocardiography Laboratory
- Institute of Preventive Pediatrics, Technical University of Munich, Munich, Germany
- Hypertension and Vascular Risk Unit, Internal Medicine Department, Hospital Clinic of Barcelona, Spain
- Unitat d’Hipertensió Arterial i Risc Vascular, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain
- Nephrology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
- CARDIO HEALTH-LAB: Cardiovascular Pathophysiology and Circulatory Health Laboratory
- Italian National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa Italy
- Cardiovascular Internal Medicine, University of Bologna, Bologna, Italy
- Carvascare Research Group, Cuenca, Spain
- Early Vascular Aging General Practitioner Research Centre, Budapest, Hungary
- Cardiovascular Center, University Hospital Ghent, Belgium
- Primary Care Research Unit of Salamanca (APISAL), Salamanca, Spain
- ASKLEPIOS Study, Ghent, Belgium
- Hypertension Excellence Center, Brescia, Italy
- Laboratory of Vascular Biology, Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- Department of Clinical and Experimental Medicine, University of Pisa, Italy
- The Unit for Vascular Investigations, Vilnius University Santaros Klinikos, Lithuania
- Cardiovascular Prevention and Research Unit, Clinic and Laboratory of Pathophysiology, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens
- SDCO—Steno Diabetes Center Odense, Odense, Denmark
- Research Centre in Physical Activity, Health and Leisure (CIAFEL)
- Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany
- Research Centre of Applied and Preventive Medicine/Centre for Population Health Research, Turku, Finland
- Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
- Menopause Unit, 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece
- Hypertension and Vascular Risk Unit, Internal Medicine Service, University Hospital of Sagunto, Sagunto (Valencia), Spain
- Population Science and Experimental Medicine, Institute of Cardiovascular Science, University College London, United Kingdom
- Centre for Cardiovascular Health and Aging, Cardiff, United Kingdom
- Peripheral Vessels Unit, First Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration Hospital, Athens, Greece
- Chapter 51 b. Asia/Australia Research Centers
- Abstract
- Vascular Research Section, Department of Cardiology, Tokyo Medical University, Tokyo, Japan
- Jichi Medical University Center of Excellence in Community Medicine Cardiovascular Research and Development (JCARD), Tochigi, Japan
- Blood Pressure and Arterial Function (BPAF) Laboratory, Macquarie Medical School, Macquarie University, Sydney, Australia
- Menzies Institute for Medical Research, Hobart, Australia
- Menzies Institute for Medical Research, Hobart, Australia
- Miyagi University of Education Medical Center, and Tohoku University Graduate School of Medicine, Sendai, Japan
- Chapter 52 c. North American Research Centers
- Abstract
- History of North American Artery Society
- Preventive Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
- Iowa Translational Vascular Physiology Lab, Department of Health and Human Physiology, University of Iowa, Iowa City, United States
- Chirinos Lab at the University of Pennsylvania
- Integrative Human Physiology Laboratory, University of Massachusetts Boston, Boston, MA, United States
- Aging and Vascular Physiology Lab, Eugene, OR, United States
- UNC Cardiometabolic Lab, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
- Integrative Physiology Laboratory, University of Illinois at Chicago, United States
- Chapter 53 d. Latin American Research Centers
- Abstract
- ARTERY LATAM Society: Brief Historical Summary
- Clinic of Hypertension and Associated Metabolic Diseases—CHAMA, Rio de Janeiro, Brazil
- Hypertension Unity—Instituto do Coração do HCFMUSP, São Paulo, Brazil
- Hypertension Unit. Cardiology Department, Medicine School, Federal University of Goias, Brazil
- Research Group on Hypertension, Arterial Stiffness and Vascular Aging (GPHARV), Maringa, Brazil
- Vascular Research Center and Its Risk Factors Vascor, Salvador, Bahia, Brazil
- Laboratory of Vascular Dynamics and Non-Invasive Hemodynamics. Hosp. São Francisco—Santa Casa de Porto Alegre—Brazil
- Cardiometabolic Center Dr. Luis María Pupi, Ciudad Autónoma de Buenos Aires, Argentina
- CardioArenales: Noninvasive Vascular Laboratory
- Centro de Hipertensión Arterial y Biomecânica Vascular
- SICOR Clinical and Research Center, Medellin, Colombia
- Metabolism and Biomechanics in Systemic Vasculopathy
- Arterial Stiffness Laboratory
- University Hospital, Fundación Favaloro, Arterial Hypertension, Metabolic Unit
- Ricardo Gutierrez Children´s Hospital, Buenos Aires, Argentina
- Masira Research Institute, Medical School, Universidad de Santander (UDES), Bucaramanga, Colombia
- Chapter 54 e. Network for Research in Vascular Aging
- Abstract
- Acknowledgment
- Introduction and Motivation
- Research Efforts and Achievements
- Challenges
- Outlook
- References
- Index
- No. of pages: 770
- Language: English
- Edition: 2
- Published: February 29, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443155123
- eBook ISBN: 9780443155130
PC
Pedro Guimarães Cunha
Prof. Pedro Guimarães Cunha is a Consultant in Internal Medicine and a European Hypertension Specialist (by the European Society of Hypertension). He works as a Professor and Researcher of Minho Medical School and the Life and Health Sciences Research Institute, Minho University. He coordinates the Outpatient Clinic and Research of the Center for the Research and Treatment of Arterial Hypertension and Cardiovascular Risk, Hospital Senhora da Oliveira - Guimarães / Minho University (an ESH Excellence Center in Hypertension). He has served as President of the Working Group Hypertension and Brain - European Society of Hypertension (2018-2022) and is currently the Secretary General of the Executive Committee of the Artery Society. His main focus is clinical research in vascular aging, large arteries, cardiovascular risk, hypertension, cardiometabolic and cardiovascular disease.
PB
Pierre Boutouyrie
Pierre Boutouyrie is full professor of Pharmacology at Université de Paris Cité, head of Pharmacology department and cardiologist at Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, and researcher at Institut National de Santé et recherche médicale INSERM, PARCC. His main topics are care and research in hypertension, research on arterial remodeling and stiffness. He has published over 340 articles and has over 20,000 quotations.
MO
Michael Hecht Olsen
Michael Hecht Olsen is a professor in Hypertension and Cardiovascular Prevention at the Department for Regional Health Research, University of Southern Denmark, and senior consultant in cardiology at Department of Medicine 1, Holbaek Hospital, Denmark.
Both clinically and in research, he works with hypertension, obesity, diabetes and cardiovascular risk stratification using measurements of subclinical cardiovascular damage (e.g., pulse wave analysis, ultrasound of the carotid arteries and echocardiography) and new biomarkers for deep phenotyping trying to develop individualized treatment. He has published over 200 publications (Web of Science H-index 47).
PN
Peter M Nilsson
Peter M. Nilsson is Senior Professor/expert in Clinical Cardiovascular Research at Lund University, Department of Clinical Sciences, Skåne University Hospital, Malmö, Sweden. For many years he has been developing the concept of EVA with numerous colleagues and the prevention of cardiovascular disease and type 2 diabetes.
SL
Stephane Laurent
Stepane Laurent’s research interests are hypertension pathophysiology and management, pharmacology of antihypertensive drugs, arterial stiffness and vascular ageing. He has served as President of the European Society of Hypertension (ESH) (2007-2009) and President of the ARTERY Society (2010-2012), and is the author of over 500 referenced articles and 20 chapters in books.